{
    "accountDetails": {
        "accountHasCodexViolations": false,
        "activeDateRanges": [
            {
                "fromDate": "2022-11-02T11:14:42.000+01:00",
                "untilDate": "2024-07-02T00:23:06.000+02:00"
            }
        ],
        "firstPublicationDate": "2022-11-02T11:14:42.000+01:00",
        "inactiveDateRanges": [
            {
                "fromDate": "2024-07-02T00:23:06.000+02:00"
            }
        ],
        "lastUpdateDate": "2023-07-13T14:54:07.000+02:00",
        "registerEntryVersions": [
            {
                "activeUntilDate": "2024-07-02T00:23:06.000+02:00",
                "legislation": "GL2022",
                "registerEntryId": 23589,
                "validFromDate": "2023-07-13T14:54:07.000+02:00",
                "version": 3,
                "versionActiveLobbyist": false
            },
            {
                "legislation": "GL2022",
                "registerEntryId": 16037,
                "validFromDate": "2023-07-11T07:50:56.000+02:00",
                "validUntilDate": "2023-07-13T14:54:07.000+02:00",
                "version": 2,
                "versionActiveLobbyist": true
            },
            {
                "legislation": "GL2022",
                "registerEntryId": 8910,
                "validFromDate": "2022-11-02T11:14:42.000+01:00",
                "validUntilDate": "2023-07-11T07:50:56.000+02:00",
                "version": 1,
                "versionActiveLobbyist": true
            }
        ]
    },
    "activeLobbyist": false,
    "activitiesAndInterests": {
        "activity": {
            "code": "ACT_ORGANIZATION",
            "de": "Unternehmen",
            "en": "Company"
        },
        "activityDescription": "Die Novocure GmbH in Deutschland ist Teil eines globalen Onkologieunternehmens. Weltweit wurden bereits \u00fcber 25.000 Patientinnen und Patienten mit unserer innovativen Krebstherapie Tumor Treating Fields (TTFields) behandelt.\r\n\r\nGemeinsam mit unseren Patientinnen und Patienten streben wir danach, das \u00dcberleben bei einigen der aggressivsten Formen von Krebs zu verl\u00e4ngern - durch die Entwicklung und den Vertrieb unserer Therapieplattform. \r\n\r\nTTFields ist in Deutschland eine Leistung der gesetzlichen Krankenkassen zur Therapie des neu diagnostizierten Glioblastoms (GBM), einem aggressiven Hirntumor.\r\n\r\nNovocures TTFields-Therapiesysteme sind in Europa CE-zertifiziert zur Behandlung des neu diagnostizierten und des rezidivierenden Glioblastoms sowie zur Behandlung des Pleuramesothelioms, einer schwer zu behandelnden Krebserkrankung des Rippenfells.\r\n\r\nIn laufenden Studien im pr\u00e4klinischen und klinischen Bereich zeigt TTFields bei weiteren soliden Tumorarten vielversprechende Ergebnisse, darunter auch einige der aggressivsten Formen von Krebs.",
        "activityOperationType": "BOTH",
        "fieldsOfInterest": [
            {
                "code": "FOI_MEDIA_PRIVACY",
                "de": "Datenschutz und Informationssicherheit",
                "en": "Data protection and information security"
            },
            {
                "code": "FOI_ECONOMY_INDUSTRIAL",
                "de": "Industriepolitik",
                "en": "Industrial policy"
            },
            {
                "code": "FOI_HEALTH_PROMOTION",
                "de": "Gesundheitsf\u00f6rderung",
                "en": "Health promotion"
            },
            {
                "code": "FOI_ECONOMY",
                "de": "Wirtschaft",
                "en": "Economy"
            },
            {
                "code": "FOI_EUROPEAN_UNION",
                "de": "Europapolitik und Europ\u00e4ische Union",
                "en": "European politics and the EU"
            },
            {
                "code": "FOI_HEALTH_OTHER",
                "de": "Sonstiges im Bereich \"Gesundheit\"",
                "en": "Other in the field of \"Health\""
            },
            {
                "code": "FOI_SS_HEALTH",
                "de": "Krankenversicherung",
                "en": "Health insurance"
            },
            {
                "code": "FOI_HEALTH",
                "de": "Gesundheit",
                "en": "Health"
            },
            {
                "code": "FOI_SOCIAL_SECURITY",
                "de": "Soziale Sicherung",
                "en": "Social security"
            },
            {
                "code": "FOI_MEDIA",
                "de": "Medien, Kommunikation und Informationstechnik",
                "en": "Media, communication and information technology"
            },
            {
                "code": "FOI_EU_DOMESTIC_MARKET",
                "de": "EU-Binnenmarkt",
                "en": "EU internal market"
            },
            {
                "code": "FOI_SCIENCE_RESEARCH_TECHNOLOGY",
                "de": "Wissenschaft, Forschung und Technologie",
                "en": "Science, research and technology"
            },
            {
                "code": "FOI_WORK",
                "de": "Arbeit und Besch\u00e4ftigung",
                "en": "Work and employment"
            },
            {
                "code": "FOI_WORK_POLICY",
                "de": "Arbeitsmarkt",
                "en": "Job market"
            },
            {
                "code": "FOI_HEALTH_SUPPLY",
                "de": "Gesundheitsversorgung",
                "en": "Health supply"
            }
        ],
        "legislativeProjects": []
    },
    "annualReports": {
        "annualReportExists": true,
        "disclosureRequirementsExist": true,
        "locationOfReportPublication": "www.bundesanzeiger.de",
        "reportWasPublishedElsewhere": true
    },
    "clientIdentity": {
        "clientsPresent": false
    },
    "codeOfConduct": {
        "ownCodeOfConduct": false
    },
    "donators": {
        "donatorsInformationPresent": false,
        "fiscalYearCompleted": true,
        "fiscalYearEnd": "2022-12",
        "fiscalYearStart": "2022-01",
        "refuseDonatorsInformation": false
    },
    "employeesInvolvedInLobbying": {
        "employeesCount": {
            "from": 1,
            "to": 10
        }
    },
    "financialExpenses": {
        "financialExpensesEuro": {
            "from": 150001,
            "to": 160000
        },
        "fiscalYearCompleted": true,
        "fiscalYearEnd": "2022-12",
        "fiscalYearStart": "2022-01",
        "refuseFinancialExpensesInformation": false
    },
    "legislation": "GL2022",
    "lobbyistIdentity": {
        "address": {
            "city": "M\u00fcnchen",
            "country": {
                "code": "DE",
                "de": "Deutschland",
                "en": "Germany"
            },
            "street": "Elektrastra\u00dfe",
            "streetNumber": "6",
            "type": "NATIONAL",
            "zipCode": "81925"
        },
        "contactDetails": {
            "emails": [
                {
                    "email": "lobby.register@novocure.com"
                }
            ],
            "phoneNumber": "+49899957900",
            "websites": [
                {
                    "website": "www.novocure.de"
                }
            ]
        },
        "identity": "ORGANIZATION",
        "legalForm": {
            "code": "LF_GMBH",
            "de": "Gesellschaft mit beschr\u00e4nkter Haftung (GmbH)",
            "en": "Limited liability company (GmbH)"
        },
        "legalFormType": {
            "code": "JURISTIC_PERSON",
            "de": "Juristische Person",
            "en": "Legal person"
        },
        "legalRepresentatives": [
            {
                "commonFirstName": "Ashley",
                "emails": [
                    {
                        "email": "lobby.register@novocure.com"
                    }
                ],
                "function": "Gesch\u00e4ftsf\u00fchrer",
                "lastName": "Cordova",
                "phoneNumber": "+49899957900"
            },
            {
                "commonFirstName": "Wilco",
                "emails": [
                    {
                        "email": "lobby.register@novocure.com"
                    }
                ],
                "function": "Gesch\u00e4ftsf\u00fchrer",
                "lastName": "Groenhuysen",
                "phoneNumber": "+49899957900"
            }
        ],
        "membersPresent": false,
        "memberships": [
            {
                "membership": "Deutsche Krebsgesellschaft e.V."
            },
            {
                "membership": "Health Care Bayern e.V."
            }
        ],
        "membershipsPresent": true,
        "name": "NovoCure GmbH",
        "namedEmployees": [
            {
                "commonFirstName": "Margarethe",
                "lastName": "Gawelek-Kieback"
            },
            {
                "commonFirstName": "Tobias",
                "lastName": "Weizel"
            },
            {
                "academicDegreeAfter": "MHBA",
                "academicDegreeBefore": "Dr. med.",
                "commonFirstName": "Adrian",
                "lastName": "Kinzel"
            }
        ],
        "namedEmployeesPresent": true
    },
    "publicAllowances": {
        "fiscalYearCompleted": true,
        "fiscalYearEnd": "2022-12",
        "fiscalYearStart": "2022-01",
        "publicAllowancesPresent": false,
        "refusePublicAllowancesInformation": false
    },
    "registerEntryDetails": {
        "annualUpdate": {
            "lastAnnualUpdate": "2023-07-11T07:50:56.000+02:00",
            "updateMissing": false
        },
        "detailsPageUrl": "https://www.lobbyregister.bundestag.de/suche/R005415/23589",
        "pdfUrl": "https://www.lobbyregister.bundestag.de/media/d1/b9/222576/Lobbyregister-Detailansicht-R005415-2023-07-13_14-54-07.pdf",
        "refusedAnything": false,
        "validFromDate": "2023-07-13T14:54:07.000+02:00",
        "version": 3
    },
    "registerEntryId": 23589,
    "registerNumber": "R005415"
}